Welcome to HealthcareBanker.com

Thank you for visiting HealthcareBanker.com a news aggregator of middle-market mergers and acquisition activity in the healthcare industries. This site addresses investment banking topics dealing with M&A, Capital Raising, Borrowing/Lending and other Corporate Development and Finance activities within the Healthcare Services, Healthcare IT, Medical Device, and Life Science industries.

Tuesday, September 29, 2015

Biotech Investing Cooling Off?

Amid Biotech Swoon, Third Rock’s MyoKardia Tees up IPO

 

(from Xconomy)

Does the biotech bull market still have a pulse? MyoKardia, a three-year-old startup developing heart drugs, will soon try to find out.

The San Francisco-based company filed papers with the SEC on Monday to go public and trade on the Nasdaq under the ticker symbol “MYOK.” MyoKardia would use the cash to advance its work in drugs for certain forms of genetically triggered heart disease, like hypertrophic cardiomyopathy (HCM). And it’ll ask investors to buy into a company without a whole lot of clinical data as of yet—the first of its prospects, a drug known as MYK-461, is in Phase 1 tests that are expected to wrap up in the middle of next year.

Tuesday, September 22, 2015

Benefits of Diversifying Hospital Acquisitions



Why Hospitals Should Buy IT Startups



Execs must 'avoid the trap of viewing deals as one-off opportunities' 

Lots of hospitals are snapping up clinics and physician practices. One major consultancy recommends they also consider acquiring digital health startups and other vertically-integrated companies.

The advice comes amid a record timespan in healthcare mergers and acquisitions.

Healthcare M&A in the U.S., in fact, totaled $241 billion by May 2015, the highest year-to-date figure ever, according to a new report from Accenture. And such changes in the healthcare landscape should prompt executives to look at asset accumulation differently.

Friday, September 18, 2015

Another Massive Biotech Fund In The Works

 

OrbiMed sets its sights on a $950M blockbuster biotech fund


(from Fierce Biotech

Less than two years after OrbiMed unleashed its last big biotech fund, the venture group is going back to the well to piece together an even bigger, $950 million cache of cash.

OrbiMed outlined its plans for the blockbuster Fund VI in a filing with the SEC. A spokesperson for the group declined comment on the fund's plans when contacted by FierceBiotech, noting that the offering is ongoing.

Back in the fall of 2013, OrbiMed had set out with plans to invest $735 million in around 30 biopharma, devices and diagnostics companies, gambling up to $50 million on each. During that time, the venture player has been a prolific player while the industry has boomed around the world.

Tuesday, September 8, 2015

Molina Investing In Behavioral & Mental Health

Molina Healthcare to Acquire Providence Human Services and Providence Community Services, the Behavioral and Mental Health Subsidiaries of the Providence Service Corporation

Molina Healthcare, Inc. (NYSE: MOH) and The Providence Service Corporation (NASDAQ: PRSC) together announced today that the parties have entered into a definitive agreement whereby Molina Healthcare will acquire all the outstanding ownership interests of Providence Human Services, LLC (PHS) and Providence Community Services, LLC (PCS), both wholly owned subsidiaries of The Providence Service Corporation. Under the terms of the acquisition agreement, Molina will pay The Providence Service Corporation approximately $200 million upon the closing of the transaction, which will be subject to customary working capital adjustments. Molina intends to fund the transaction with available cash on its balance sheet. The transaction is expected to close during the fourth quarter of 2015, subject to regulatory approvals and the satisfaction of other closing conditions.